SWITCH Charts

Dec 99/Jan 2000

6

6

SWITCH^® 1999 In Review. ’99 Switches in Major Markets Equal Moderate Pace of ’98. France, the ’99 Leader in Number and Kinds of Switches, Breaks New Ground in NRT and Contraception Product. Numerous (Un)Predictable New Challengers En Route.

SWITCH^® 1999 Index. A complete list of all articles for the year.
SWITCH Special Report: All the Major Switches of 1999

Feb ‘00

6

7

A Critical Review of 1990s Switching. Two Factors that Insure OTC Switch Profitability and Reduce Risk: Product Differentiation & Timing. The “Statins” are Next.

From the Publisher: New Switching Incentives.
SWITCH Special Report: Lipid-Lowering Drugs

Mar ‘00

6

8

PART ONE: Growth of the Rx and OTC Generic Business. Best Defense via Dual Status, Then Novel Dosage Forms & Technologies.

Country Update: Canada, UK and Germany: Dual Status, Erectile Dysfunction, “Morning After” Pill, etc.

Apr ‘00

6

9

PART TWO: Generic Defense Strategies & Tactics Evolve. Traditional OTC Marketing Ploys Still Help. Rx Claritin’s Generic Suicide (Genericide)?

The FDA Initiates a Review of Switch Policy and Invites Public Opinion.
SWITCH Special Report: Generic Defense versus Dual Status Comparison

May ‘00

6

10

SPECIAL FDA SWITCH REVIEW ISSUE: FDA Questions Whether an Altered Rx-to-OTC Switch Paradigm Would Better Serve Public Health Needs. SWITCH^® Responds & Proposes Changes Intended to 1) Satisfy Stakeholders and 2) Improve Public Health.

Can Sepracor’s ICE™ Strategy Heat Up Switch Market?
SWITCH Special Report: Chronic and/or Recurrent Conditions

Jun/Jul ‘00

7

1

FDA Historic June Public Meeting — SWITCH^® Was There! Francesco International in the News.
SWITCH^® Publisher’s Report: Year 2000 Progress Report to Our SWITCH^® Readers.
SWITCH Special Report: Lipid-Lowering Agents Profile

Aug/Sept. ‘00

7

2

The Public Health Battle to Provide Broader Access to Safe Drugs. The UK’s New “Patient Group Directions” Provides Yet One More Mechanism to Bypass the Doctor Visit & Opens Up Access. Meanwhile, in the US, “OTC Setting” Test Determines Whether a “Statin” Will Switch in 2001.

Safe Access versus Restricted Distribution. Switch of Emergency Birth Control Category Will be THE Story for 2000. Long Term Rx-to-OTC Switch Impact Likely to be Greater Than Vaginal Antifungal.
Country Update: UK, US, Spain, Germany, Japan
SWITCH Special Report: Population Drivers of OTC “Morning After” Pill

Oct/Nov. ‘00

7

2

The US Pharmacist Today: Counseling Role Diminishes With Little End in Sight; Stress, Boredom & Salaries Increase. Will Widening Gap in Healthcare Counseling Benefit Rx-to-OTC Switch Industry?

European Pharmacy Business Today. The 3rd Class of Drugs Unravels Further; UK’s Resale Price Maintenance Decision Imminent
SWITCH Special Report: The Shifting Roles of Pharmacist, Physician & Consumer

DEC‘00/Jan 2001

7

3

The Breakthrough in Broadened Access: Despite a Poor Year in Switches, We Are Optimistic About the Future.
SWITCH^® 2000 In Review

The Healthcare “Sorting Out” Process Continues.
Country Update: The Year 2000 in Switches.
SWITCH^® 2000 Index. A complete list of all articles for the year.
SWITCH Special Report: All the Major Switches of 2000